New drugs under investigation for the treatment of alopecias

Jorge Ocampo-Garza, Jacob Griggs, Antonella Tosti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Alopecia is a very common complaint in medical practice, which usually has a large psychological impact in patients. Treatment of alopecia is often difficult and frustrating for patients and clinicians owing to the slow growth rate of the hair, long treatment terms, limited efficacy, and possible adverse side effects. Areas covered: This paper reviews the new and emerging treatments for two of the most common forms of alopecia, known as androgenetic alopecia and alopecia areata. A literature search of PubMed/MEDLINE and ClinicalTrial.gov was performed to gather information about active research on new treatments for alopecias. Websites of companies sponsoring clinical trials were also searched for interim result data. Expert opinion: Many new therapies in two of the most common forms of hair loss have been developed and are currently being studied with encouraging results. In alopecia areata, JAK inhibitors are promising. The discovery of JAK inhibitors has prompted the research and identification of new molecules. In androgenetic alopecia, we are still looking for a topical treatment that is superior to topical minoxidil. However, stem-cell research is advancing and the goal to create new follicles or refresh dormant follicles may be realized in the near future.

Original languageEnglish (US)
Pages (from-to)275-284
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume28
Issue number3
DOIs
StatePublished - Mar 4 2019

Fingerprint

Alopecia
Pharmaceutical Preparations
Alopecia Areata
Therapeutics
Minoxidil
Stem Cell Research
Expert Testimony
Research
PubMed
MEDLINE
Hair
Clinical Trials
Psychology
Growth

Keywords

  • Alopecia
  • alopecia areata
  • androgenetic alopecia
  • baricitinib
  • bimatoprost
  • BNZ-1
  • JAK inhibitors
  • latanoprost
  • ruxolitinib
  • setipiprant
  • tofacitinib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New drugs under investigation for the treatment of alopecias. / Ocampo-Garza, Jorge; Griggs, Jacob; Tosti, Antonella.

In: Expert Opinion on Investigational Drugs, Vol. 28, No. 3, 04.03.2019, p. 275-284.

Research output: Contribution to journalArticle

Ocampo-Garza, Jorge ; Griggs, Jacob ; Tosti, Antonella. / New drugs under investigation for the treatment of alopecias. In: Expert Opinion on Investigational Drugs. 2019 ; Vol. 28, No. 3. pp. 275-284.
@article{09c1a5de2212445ca21b1b1731b895b2,
title = "New drugs under investigation for the treatment of alopecias",
abstract = "Introduction: Alopecia is a very common complaint in medical practice, which usually has a large psychological impact in patients. Treatment of alopecia is often difficult and frustrating for patients and clinicians owing to the slow growth rate of the hair, long treatment terms, limited efficacy, and possible adverse side effects. Areas covered: This paper reviews the new and emerging treatments for two of the most common forms of alopecia, known as androgenetic alopecia and alopecia areata. A literature search of PubMed/MEDLINE and ClinicalTrial.gov was performed to gather information about active research on new treatments for alopecias. Websites of companies sponsoring clinical trials were also searched for interim result data. Expert opinion: Many new therapies in two of the most common forms of hair loss have been developed and are currently being studied with encouraging results. In alopecia areata, JAK inhibitors are promising. The discovery of JAK inhibitors has prompted the research and identification of new molecules. In androgenetic alopecia, we are still looking for a topical treatment that is superior to topical minoxidil. However, stem-cell research is advancing and the goal to create new follicles or refresh dormant follicles may be realized in the near future.",
keywords = "Alopecia, alopecia areata, androgenetic alopecia, baricitinib, bimatoprost, BNZ-1, JAK inhibitors, latanoprost, ruxolitinib, setipiprant, tofacitinib",
author = "Jorge Ocampo-Garza and Jacob Griggs and Antonella Tosti",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/13543784.2019.1568989",
language = "English (US)",
volume = "28",
pages = "275--284",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - New drugs under investigation for the treatment of alopecias

AU - Ocampo-Garza, Jorge

AU - Griggs, Jacob

AU - Tosti, Antonella

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Introduction: Alopecia is a very common complaint in medical practice, which usually has a large psychological impact in patients. Treatment of alopecia is often difficult and frustrating for patients and clinicians owing to the slow growth rate of the hair, long treatment terms, limited efficacy, and possible adverse side effects. Areas covered: This paper reviews the new and emerging treatments for two of the most common forms of alopecia, known as androgenetic alopecia and alopecia areata. A literature search of PubMed/MEDLINE and ClinicalTrial.gov was performed to gather information about active research on new treatments for alopecias. Websites of companies sponsoring clinical trials were also searched for interim result data. Expert opinion: Many new therapies in two of the most common forms of hair loss have been developed and are currently being studied with encouraging results. In alopecia areata, JAK inhibitors are promising. The discovery of JAK inhibitors has prompted the research and identification of new molecules. In androgenetic alopecia, we are still looking for a topical treatment that is superior to topical minoxidil. However, stem-cell research is advancing and the goal to create new follicles or refresh dormant follicles may be realized in the near future.

AB - Introduction: Alopecia is a very common complaint in medical practice, which usually has a large psychological impact in patients. Treatment of alopecia is often difficult and frustrating for patients and clinicians owing to the slow growth rate of the hair, long treatment terms, limited efficacy, and possible adverse side effects. Areas covered: This paper reviews the new and emerging treatments for two of the most common forms of alopecia, known as androgenetic alopecia and alopecia areata. A literature search of PubMed/MEDLINE and ClinicalTrial.gov was performed to gather information about active research on new treatments for alopecias. Websites of companies sponsoring clinical trials were also searched for interim result data. Expert opinion: Many new therapies in two of the most common forms of hair loss have been developed and are currently being studied with encouraging results. In alopecia areata, JAK inhibitors are promising. The discovery of JAK inhibitors has prompted the research and identification of new molecules. In androgenetic alopecia, we are still looking for a topical treatment that is superior to topical minoxidil. However, stem-cell research is advancing and the goal to create new follicles or refresh dormant follicles may be realized in the near future.

KW - Alopecia

KW - alopecia areata

KW - androgenetic alopecia

KW - baricitinib

KW - bimatoprost

KW - BNZ-1

KW - JAK inhibitors

KW - latanoprost

KW - ruxolitinib

KW - setipiprant

KW - tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=85060629634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060629634&partnerID=8YFLogxK

U2 - 10.1080/13543784.2019.1568989

DO - 10.1080/13543784.2019.1568989

M3 - Article

C2 - 30642204

AN - SCOPUS:85060629634

VL - 28

SP - 275

EP - 284

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -